Management of the dialysis patient in general intensive care

被引:24
作者
Arulkumaran, N. [1 ]
Montero, R. M. [1 ]
Singer, M. [2 ]
机构
[1] Univ London Imperial Coll Sci Technol & Med, Dept Nephrol, Div Med, Hammersmith Hosp, London W12 0HS, England
[2] UCL, Bloomsbury Inst Intens Care Med, London, England
关键词
cardiovascular; electrolyte; end-stage renal disease; pharmacology; sepsis; STAGE RENAL-DISEASE; CRITICALLY-ILL PATIENTS; CHRONIC KIDNEY-DISEASE; IMPLANTABLE CARDIOVERTER-DEFIBRILLATORS; RESISTANT STAPHYLOCOCCUS-AUREUS; CARDIAC TROPONIN-T; HEMODIALYSIS-PATIENTS; PERITONEAL-DIALYSIS; UNITED-STATES; INFECTIOUS COMPLICATIONS;
D O I
10.1093/bja/aer461
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
The incidence of end-stage renal disease (ESRD) is rising and represents an important group of patients admitted to intensive care units (ICU). ESRD patients have significant co-morbidities and specific medical requirements. Renal replacement therapy (RRT), cardiovascular disease, disorders of electrolytes, drug metabolism, and sepsis are discussed. This review provides a practical approach to problems specific to the ESRD patient and common problems on ICU that require special consideration in ESRD patients. ESRD patients are at risk of hyperkalaemia. I. V. insulin and nebulized salbutamol lower serum potassium until definitive treatment with RRT is instituted. ESRD patients are prone to hypocalcaemia, which requires i.v. replacement if associated with complications. Midazolam has delayed metabolism and elimination in renal impairment and should be avoided. Morphine and its derivatives accumulate in renal failure and shorter-acting opiates are preferable. The use of diuretics is limited to patients with residual urine output. When required, therapeutic systemic anticoagulation should be achieved with unfractionated heparin as it is reversible and its metabolism and clearance are independent of renal function. The risk of sepsis is higher among ESRD patients when compared with patients with normal renal function. Empiric treatment should include both Gram-positive and Gram-negative cover, and methicillin-resistant Staphylococcus aureus cover if the patient has a dialysis catheter. Cardiovascular events account for the majority of deaths among ESRD patients. Troponin-I and CK-MB in combination should be used as markers of acute myocardial damage in the appropriate context, whereas B-type natriuretic peptide and troponin-T values are of less value.
引用
收藏
页码:183 / 192
页数:10
相关论文
共 109 条
[1]   Stage IV Chronic Kidney Disease [J].
Abboud, Hanna ;
Henrich, William L. .
NEW ENGLAND JOURNAL OF MEDICINE, 2010, 362 (01) :56-65
[2]   ALBUTEROL AND INSULIN FOR TREATMENT OF HYPERKALEMIA IN HEMODIALYSIS-PATIENTS [J].
ALLON, M ;
COPKNEY, C .
KIDNEY INTERNATIONAL, 1990, 38 (05) :869-872
[3]   Diuretics in renal failure [J].
Andreucci, M ;
Russo, D ;
Fuiano, G ;
Minutolo, R ;
Andreucci, VE .
MINERAL AND ELECTROLYTE METABOLISM, 1999, 25 (1-2) :32-38
[4]  
[Anonymous], J OPIOID MANAGE
[5]   Comparison of infectious complications between incident hemodialysis and peritoneal dialysis patients [J].
Aslam, Nabeel ;
Bernardini, Judith ;
Fried, Linda ;
Burr, Renee ;
Piraino, Beth .
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2006, 1 (06) :1226-1233
[6]   Chronic kidney disease in the developing world [J].
Barsoum, RS .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (10) :997-999
[7]   Removal of morphine but not fentanyl during haemodialysis [J].
Bastani, B ;
Jamal, JA .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 1997, 12 (12) :2802-2804
[8]   Pyocystis in patients on chronic dialysis. A potentially misdiagnosed syndrome [J].
Bibb J.L. ;
Servilla K.S. ;
Gibel L.J. ;
Kinne J.E. ;
White R.E. ;
Hartshsorne M.F. ;
Tzamaloukas A.H. .
International Urology and Nephrology, 2002, 34 (3) :415-418
[9]   Antibiotic dosing during sustained low-efficiency dialysis: Special considerations in adult critically ill patients [J].
Bogard, Kimberly N. ;
Peterson, Nicole T. ;
Plumb, Troy J. ;
Erwin, Michael W. ;
Fuller, Patrick D. ;
Olsen, Keith M. .
CRITICAL CARE MEDICINE, 2011, 39 (03) :560-570
[10]   Pharmacokinetics of midazolam and its main metabolite 1-hydroxymidazolam in intensive care patients [J].
Boulieu, R ;
Lehmann, B ;
Salord, F ;
Fisher, C ;
Morlet, D .
EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 1998, 23 (02) :255-258